Patents by Inventor Daniel B. DIX

Daniel B. DIX has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Stabilized Formulations Containing Anti-Interleukin-6 Receptor (IL-6R) Antibodies
    Publication number: 20160002341
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Application
    Filed: September 22, 2015
    Publication date: January 7, 2016
    Inventors: Daniel B. Dix, Kenneth S. Graham, Douglas Kamen, Scott M. Walsh
  • Stabilized formulations containing anti-PCSK9 antibodies
    Patent number: 9193801
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (PCSK9). The formulations may contain, in addition to an anti-PCSK9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: November 24, 2015
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Scott M. Walsh, Daniel B. Dix
  • Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies
    Patent number: 9173880
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Grant
    Filed: January 7, 2011
    Date of Patent: November 3, 2015
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel B. Dix, Kenneth S. Graham, Douglas Kamen, Scott M. Walsh
  • Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies
    Publication number: 20150100030
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-4 receptor (hIL-4R). The formulations may contain, in addition to an anti-hIL-4R antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Application
    Filed: December 19, 2014
    Publication date: April 9, 2015
    Inventors: Daniel B. Dix, Xiaolin Tang
  • Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies
    Patent number: 8945559
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-4 receptor (hIL-4R). The formulations may contain, in addition to an anti-hIL-4R antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Grant
    Filed: October 5, 2011
    Date of Patent: February 3, 2015
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel B. Dix, Xiaolin Tang
  • Stabilized Formulations Containing Anti-PCSK9 Antibodies
    Publication number: 20140341928
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (PCSK9). The formulations may contain, in addition to an anti-PCSK9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Application
    Filed: June 30, 2014
    Publication date: November 20, 2014
    Inventors: Scott M. Walsh, Daniel B. Dix
  • Stabilized Formulations Containing Anti-Ang2 Antibodies
    Publication number: 20130186797
    Abstract: The present invention provides pharmaceutical formulations comprising an antibody that specifically binds to angiopoietin 2 (Ang-2). The formulations may contain, in addition to an anti-Ang-2 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months and after being subjected to thermal and other physical stress.
    Type: Application
    Filed: January 22, 2013
    Publication date: July 25, 2013
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Scott M. WALSH, Daniel B. DIX
  • Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies
    Publication number: 20120097565
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-4 receptor (hIL-4R). The formulations may contain, in addition to an anti-hIL-4R antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Application
    Filed: October 5, 2011
    Publication date: April 26, 2012
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Daniel B. DIX, Xiaolin TANG
  • Stabilized Formulations Containing Anti-Interleukin-6 (IL-6) Antibodies
    Publication number: 20110171241
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Application
    Filed: January 7, 2011
    Publication date: July 14, 2011
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel B. DIX, Kenneth S. Graham, Douglas Kamen, Scott M. Walsh